Civica Rx raised a few eyebrows in 2018, when it was founded as a not-for-profit to manufacture important generic medicines for the US market. But, since then, the company has gone from strength to strength – 18 medicines are now in production or shipped for use in hospitals across the USA.
A recent announcement from the company draws attention to the signing of a long-term (seven-year) agreement with Thermo Fisher Scientific, which will drive the development of Civica-owned Abbreviated New Drug Applications (ANDAs). Initially, the collaboration will focus on nine critical medications that have been in short supply or where the drug supply chain is considered fragile because there are too few manufacturers making the drugs.
The company also notes its interest in talking to generic drug manufacturers who are considering retiring or withdrawing their ANDA for essential medicines that are at risk of being in short supply.
Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.
